Avadel Pharmaceuticals price target lowered to $25 from $27 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Avadel Pharmaceuticals (AVDL) to $25 from $27 and keeps a Buy rating on the shares following the Q3 report. The firm sees Avadel shares as substantially undervaluing Lumryz in narcolepsy alone.